Introduction
Prostate cancer is the most common cancer in American males of all ages and the second leading cause of deaths in males from malignant disease. 1 The multistep process of human prostate tumorigenesis leading from prostate epithelial transformation of an androgen-dependent, nonmetastatic cell to a highly tumorigenic, metastatic, androgen-independent phenotype encompasses intrinsic genetic changes. These changes include activation of dominantly acting oncogenes that promote cell proliferation and loss of tumor suppressor genes that regulate cell proliferation and apoptosis. In the normal prostate, organ homeostasis is maintained by a balance between cell proliferative activities and apoptotic rate of cell death, primarily among the glandular epithelial cells. Abnormalities in prostate apoptosis among these cell populations contribute to tumorigenic growth by allowing cell proliferation to exceed cell death, potentially by leading to clonal expansion of preneoplastic cells. Early morphological evidence documented the ability of prostate tumor epithelial cells to escape the negative growth restrictions imposed by apoptosis in favor of cell proliferation, by recruiting overexpression of survival factors such as bcl-2.
2,3
Prostatic intraepithelial neoplasia (PIN) is primarily accepted by a critical mass of genitourinary pathologists as a morphologically identifiable early stage in prostate carcinogenesis. 4 It is defined as intraluminal proliferation of the secretory cells of prostatic glands. Two grades are traditionally classified for PIN: low-grade PIN (LGPIN), and high-grade PIN (HGPIN). 5 In LGPIN, the nuclei are enlarged, vary in size, having a normal or slightly increased chromatin content, and possess small or inconspicuous nucleoli. In HGPIN, cells have large nuclei of relatively uniform size, and possess prominent nucleoli that are similar to those of carcinoma cells. The basal cell layer, while intact or rarely interrupted in LGPIN, may have frequent interruptions in high-grade lesions. Four types of HGPIN structure have been histologically described: flat, rufting, micropapillary, and cribriform. Epidemiologically, the incidence and extent of both HGPIN and prostate carcinoma increasee with the age of patients. 6 Histopathologically, HGPIN and prostatic carcinoma are both multifocal and share a similar location in the peripheral zone. Cytogenetic studies implicate chromosomal alterations, proliferation activity, and expression of growth factors and respective receptors, as intermediate molecular changes in the transition from HGPIN and benign disease to prostate adenocarcinoma. 4 Bostwick reported the incidence of HGPIN is about 9% of prostate biopsies, 7 that is translated into approximately 115 000 new cases of HGPIN diagnosed each year. This review will encompass the alterations of apoptosis signaling effectors in HGPIN, availability and suitability of molecular biomarkers of PIN for early diagnosis of prostate cancer, and targeting PIN-related as an early therapeutic intervention to prevent prostate cancer progression.
Discussion
Deregulation of apoptotic and proliferative pathways in HGPIN The first report on the characterization of the PIN as a premalignant lesion came from McNeal and Bostwick almost two decades ago, 8, 9 and since then it has been accepted that HGPIN as an early lesion identified by needle biopsy evaluation for the presence of prostate carcinoma. In HGPIN, one of the characteristics that mimic prostate cancer is the multifocal nature of the lesion. 10 Comprehensive evaluation of 195 wholemounted radical prostatectomy specimens by Qian et al 10 revealed that 64.5% of cases were multicentric. The small size of the foci, and the remarkable morphologic heterogeneity, have limited the detailed characterization of the genetic alterations in PIN and its causal association with prostate cancer. Recent molecular advances, however, utilizing the laser capture microdissection technology, in combination with multiple sampling of related archival paraffin-embedded tissues from benign proliferative prostatic epithelium, PIN and prostate cancer, have allowed comparative analysis of the genetic alterations in foci of premalignant and malignant lesions in the same prostate. 11 Comparative dissection of the apoptosis status and expression profile of key apoptotic regulators among foci of highly proliferative benign prostatic epithelium, PIN and prostate adenocarcinoma from adjacent areas of the same gland are likely to provide a direct and valuable insight into the dysfunctional apoptosis events contributing to prostate carcinogenesis.
Our own recent immunohistochemical studies investigated the incidence of apoptosis among pathologically confirmed areas of benign hyperplasia, HGPIN, and prostate carcinoma in a series of prostate tissue specimens from patients who underwent prostatectomy for localized prostate cancer. 12 A characteristic immunohistochemical detection of TUNEL-positive cells in benign, premalignant and malignant prostate epithelial cells is shown in Figure 1 . Quantitative evaluation of the apoptotic index revealed significantly higher value in the benign hypertrophic glandular (26.3%) compared to adjacent areas of HGPIN (7.6%), and prostate carcinoma glands (3.1%) (Figure 2 ). Furthermore, this reduced apoptotic index among the epithelial cell populations in HGPIN and prostate carcinoma foci correlated with decreased PSA immunoreactivity.
Morphological studies have established the differences in the apoptotic status between benign and prostate cancer specimens. 2, 3, 13 Our observations could provide the molecular basis for promising 'refinery' step in the identification of the pathological transition from HGPIN to prostate carcinoma.
Apoptotic profile of PIN: precision value in early prostate cancer detection
Modifications in the expression of critical markers of the apoptotic signaling pathway could serve as a reliable index for diagnosis before or at the time of biopsy and may assist in the selection of the most appropriate therapy. 14,15. p53 serves as the checkpoint of cellular behavior by regulating cell cycle progression and apoptotic cell death at both G1 and G2 phases of the cell cycle. It is well documented that p53-mediated growth arrest prevents the replication of damaged DNA and reduces genetic instability, whereas apoptosis induced by p53 is necessary for elimination of transformed cells. Mutation in the p53 gene lead to a prolonged half-time of the protein, which becomes detectable on immunohistochemical evaluation. In prostate carcinoma, p53 expression levels have been reported
Significance of apoptosis in PIN and prostate cancer L Zeng and N Kyprianou to vary between 47 and 80%. 16, 17 Significantly enough this mutant p53 expression correlates with tumor progression, recurrence, and overall prognosis compared to lesions lacking p53 mutations. [18] [19] [20] The reports on the status of p53 expression in HGPIN have been more conflicting however. One study demonstrated that less than 6% HGPIN specimens are positive for mutant p53, 21 while others reported expression of mutant p53 in 56% of HGPIN and 72% of prostate tumors. 22 In our recent immunohistochemical evaluation, the incidence of mutant p53 expression status within the context of apoptosis deregulation in HGPIN, revealed lack of significant changes in p53 levels in HGPIN compared to adjacent areas of prostate carcinoma. 12 These results easily argue against the notion that a mutated p53 is an early event in the malignant transformation of normal prostate epithelium; such a concept would gain indirect support from existing evidence that apoptosis deregulation in premalignant and malignant prostate epithelium occurs via p53-independent pathways. 18 Transforming growth factor-b (TGF-b) is a multifunctional growth factor involved in the regulation of proliferation, differentiation, extracellular matrix formation, hematopoiesis, and angiogenesis. 23, 24 TGF-b plays an important role but with a double-agent identity, serving as a regulator of prostate cell proliferation and promotes early stages of prostate tumorigenesis, while promoting angiogenesis and metastasis during the late stages of advanced prostate cancer. [25] [26] [27] TGF-b binds to its membrane-bound receptors, TGF-b receptors (TbRI and TbRII), which form a heterotetrameric complex. After phosphorylated by TbRII, TbRI phosphorylates the receptor-activated Smad proteins (Smad2 and Smad3). Once activated, Smad2 and Smad3 form a heteromeric complex with the co-Smad, Smad4 and then, this complex translocates into the nucleus to regulate gene expression in cooperation with different transcriptional partners. 28 Defects in the TGF-b signaling pathway has been found in many human tumors, due to either loss of expression or mutational inactivation of TGF-b receptors 29 or one of the downstream elements of the pathway (such as the Smads). A marked downregulation in TbRI and TbRII receptors has been documented in prostate tumors 30, 31 providing a mechanistic link to the development of TGFb resistance during prostate tumorigenensis. Indeed, a significant loss in TbRII protein has been recently demonstrated in HGPIN and prostate carcinoma compared to the benign glands, in full accordance with existing evidence on the loss of TbRII expression during clinical progression of prostate cancer. 30 TbRII could serve as a potentially marker to identify the prostate epithelium with HGPIN with early gene mutation or deletion. 32 Within the context of a possible cross-talk between TGF-b signaling and the androgen axis, consideration must be given to evidence that androgen deprivation results in elevated nuclear Smad4 and the cytoplasmic Smad2 and Smad3 in rat normal and prostate tumor, 33 indicating a potential androgenic regulation of Smads and their temporal correlation with induction of prostate epithelial cell apoptosis.
The p27 Kip1 gene regulates progression of cell cycle from G1 to S phase by binding to and inhibiting the cyclin E/cdk2 complex. Cyclin E is a late G1 cyclin, which along with its catalytic subunit cdk2, is involved in phosphorylation of Rb, and cyclin E/cdk2 complex Significance of apoptosis in PIN and prostate cancer L Zeng and N Kyprianou determines cell entry into the S phase. p27 Kip1 is primarily regulated by alterations in translation as well as post-translational processing. 34, 35 Low levels of p27 Kip1 protein presumably interfere with the ability of cancer cells to halt cell cycling and lead to the accumulation of additional genetic alterations and more malignant growth potential. 36 A direct correlation between loss of p27 Kip1 expression and prostate tumor progression has been firmly established. 35, 37 A compelling body of evidence has established that reduced expression of p27 Kip1 predicts a shorter disease-free or survival in patients with breast, lung, gastric, esophagus, colon, and bladder cancer. [38] [39] [40] [41] Moreover, p27 Kip1 loss serves as an excellent prognostic marker associated with increased recurrence and decreased survival in prostate cancer patients. 42, 43 It is thus tempting to speculate on an early downregulation of p27 Kip1 in HGPIN epithelium, as one of the underlying changes contributing to the development of premalignant highly proliferative lesion of prostate carcinoma as illustrated in Figure 3 . A significant decrease in p27
Kip1 expression in areas of HGPIN (as a premalignant condition) was first reported by De Marzo et al. 44 These investigators reported that 11 cases of HGPIN had a consistent downregulation of p27 Kip1 as compared to adjacent benign prostatic epithelium. In addition, approximately 50-75% epithelial cells in HGPIN areas exhibited significantly reduced or total loss of p27 Kip1 nuclear expression, while in most cases, there was increased cytoplasmic staining compared with the normal appearing epithelial secretory cells. Such a downregulation of p27 Kip1 in the nuclei of HGPIN cells could be due to proteolytic degradation of p27 Kip1 as it has been demonstrated in other cancers. 40 The F-box protein Skp2 is a positive regulator of G1-S transition and promotes ubiquitin-mediated proteolysis p27 Kip1 . 45, 46 Inappropriate expression of Skp2 in G 0 cells can promote S-phase entry concomitant with loss of p27 Kip1 . There is growing in vitro and in vivo evidence identifying Skp2 overexpression in malignant lesions. [47] [48] [49] In a large sampled tissue microarray study, significant elevation in Skp2 was found in HGPIN lesions relative to benign prostate glandular epithelium. 49 A marked Skp2 overexpression was also found in prostate carcinoma that positively correlates with Gleason score and preoperative PSA levels. 49 In addition, the significant inverse relationship between p27 Kip1 and Skp2 labeling index, 49 identifies Skp2 as the specific component of the E3 ubiquitin ligase responsible for p27 Kip1 destruction in prostate tumors (Figure 3 ).
Targeting HGPIN for prostate cancer prevention
Several lines of epidemiological evidence link age and race distribution of HGPIN with prostate cancer. Direct and valuable information on the subject matter stems from an autopsy-based series of studies, reporting on the frequency of HGPIN in 180 African-Brazilian compared to Caucasian-Brazilian men. 50 Interestingly enough, while there was no significant difference between the incidence of HGPIN the two races, a tendency towards more extensive and diffused HGPIN at a younger age was detected in African-Brazilians as compared to Caucasians. 50, 51 Sakr et al 6,51 performed a comprehensive evaluation of 525 pathological autopsy specimens from men who died of trauma and 1000 patients who underwent retropubic radical prostatactomy for clinically localized prostate carcinoma. These studies revealed that HGPIN begins in young individuals in the third decade of life and increases progressively with advancing age in both African-American and Caucasian males; HGPIN, however, was more prevalent in AfricanAmericans with 7, 26, 46, 72, 75 and 91% in their third, fourth, fifth, sixth, seventh, and eighth decades, respectively. 6, 50 Additionally, HGPIN tended to be more extensive with multifocal or diffuse involvement of the gland at younger age in African-Americans compared to Caucasian males. 6 The predominant location of HGPIN was in the peripheral zone of the prostate where most moderately and poorly differentiated carcinomas arise. 6 Although 9% of men had evidence of LGPIN in their third decade of life, and the prevalence of low grade PIN increases to 20 and 44% in the fourth and fifth decades, respectively, prostate adenocarcinoma was only detected in association with HGPIN and only in men over age 40 y. 6 These observations provide a pathological-basis for the racial differences in the incidence of clinical prostate cancer, while establishing a solid identity of HGPIN as a premalignant lesion of the prostate.
Numerous experimental studies using different animal models, [52] [53] [54] [55] [56] [57] [58] as well as clinical studies involving prostate cancer patients follow-up data strongly support the causal involvement of HGPIN in the direct pathway towards prostate adenocarcinoma. After a 3-year followup, a retrospective study revealed that 31 patients had been diagnosed HGPIN, 59 while one-third of patients included in the study developed prostate cancer. 59 Studies by other investigators reported that prostate carcinoma could be found in about 40-50% cases diagnosed of HGPIN on repeat biopsy. 60, 61 In the Pb-mAR transgenic mice, a murine androgen receptor (AR) transgene regulated by the rat probasin promoter (Pb) was used to generate transgenic mice expressing elevated AR protein in prostate secretory epithelium. Transgenic mice older than 1-y developed 
Skp2 AR Figure 3 Schematic representation of the transition from normal prostate epithelium to HGPIN, and consequent to prostate carcinoma. In normal prostate, the gland is lined by two cell layers, the basal cell and the secretory luminal cell layers. In HGPIN, the secretory cells are highly proliferative with uniformly large nuclei, and increased chromatin content. The basal cell layer is notably disrupted in HGPIN. Prostate carcinoma has the common morphological characteristics of malignant epithelial cells. There is no basal cell layer.
Significance of apoptosis in PIN and prostate cancer L Zeng and N Kyprianou focal areas of intraepithelial neoplasia that strongly resemble human HGPIN. 54 This evidence provides direct proof-of-concept support that the AR can function as a positive regulator of cell proliferation in normal prostate secretory epithelium towards the development of the neoplastic phenotype. It also offers the possibility (remote as it might be) of chemoprevention or treatment of HGPIN with other antiproliferative/differentiation agents towards suppression of the clinical manifestation/progression of prostate cancer. These modalities include surgical or medical castration to lower-testosterone levels and antiandrogen treatment (with flutamide or bicalutamide), to block testosterone binding to the AR.
The estrogenic signaling pathway now emerging as a major contributor to prostate tumorigenesis, must also be considered. Studies using the transgenic mouse model TRAMP and the antiestrogen toremifene (Acapodenet), a pharmacological antagonist of the a-estrogen receptor, revealed that treatment of TRAMP mice with toremifene resulted in a reduction in the incidence of HGPIN, a significant decrease in prostate cancer, and an increase in animal survival. 62 In another study, Wang and colleagues 63 treated the a-estrogen receptor knockout mice with testosterone propionate and estradiol for 4 months. These mice developed benign prostate hyperplasia, while the control mice/wild-type group developed HGPIN and invasive prostate cancer in addition to benign prostate hyperplasia. This evidence is of major physiological relevance as it provides the first functional link for a role of a-estrogen receptor in the development of prostate cancer.
The potential targets in preventive strategies to reduce the risk of cancer involve agonists of steroid receptors (such as androgen receptor and estrogen receptor), factors downregulating inflammation (such as cyclooxygenase-2 (COX-2), inhibitors that restrain inflammatory prostaglandin synthesis, 64, 65 inducible nitric oxide synthase (iNOS) inhibitors, 66, 67 endothelin-1 inhibitors and stimulators of phase II detoxication system, [68] [69] [70] apoptosis regulators (Skp2, F-box protein), 49 insulin growth factor (IGF) signaling regulators, 71 enzymatic inhibitors (5-a-reductase), 72 and gene therapy. [73] [74] [75] A growing number of clinical studies focused on investigating the therapeutic-targeting/treatment of HGPIN as a cellular means of prevention of prostate cancer development and progression. [76] [77] [78] [79] [80] Direct clinical value is associated with two specific lines of evidence that demonstrated a significant decrease in the prevalence and extent of HGPIN after androgen deprivation therapy. 76, 81 Additional studies documented that angiogenesis in the surrounding stroma of HGPIN glands is severely decreased via suppression of vascular endothelial growth factor (VEGF) production after androgen deprivation therapy. 82 These were accompanied by substantial histopathological and immunohistochemical manifestations. 83 In benign prostate glands, AR was exclusively detected in the nuclei of glandular cells, while AR expression was present in a majority of cells in HGPIN of prostatectomy specimens (untreated and treated) 83 with both nuclear and cytoplasmic staining. After 6 months of combined androgen blockade, micropapillary and tufted architectural patterns of HGPIN was replaced by flat pattern HGPIN, and the nuclear grade of HGPIN was less than untreated group. 83 Interestingly enough, the premalignant cells in HGPIN lesion were regressed and presented as cytoplasmic clearing, prominent acinar atrophy, with a decreased ratio of acini to stroma. 83 Studies on the effect of total androgen blockage prior to radical prostatectomy revealed that HGPIN was present in only three out of 47 patients in the treated group compared to 33 out of 49 patients with no preoperative therapy. 84 Antiandrogen therapy resulted in an overall reduction in the prevalence and extent of HGPIN, although this difference was not statistically significance. 83 The decrease in the incidence of HGPIN was, however, significantly greater with 6 months or longer of antiandrogen therapy, compared with patients receiving only 3-6 months of antiandrogen therapy. 83 
Summary
The adult prostatic epithelium includes two main phenotypically distinct differentiated cell types: elongated basal cells and cuboidal/columnar luminal secretory cells (Figure 3 ). Adhesive interactions between basal cells and basal membrane (BM) is a requirement for prostatic architecture maintenance and a balanced relationship between epithelium and stroma. A complex network of steroids (androgens and estrogens) and their signaling receptors, growth factors and reciprocal interactions with the stromal cells maintains the specific phenotype of the different types of prostatic cells and the steady state of the structure and function of the prostate gland. Apoptotic profiling of HGPIN provides tremendous histological opportunities for identifying the factors contributing to deregulated prostate growth, full exploitation of which might provide considerable clinical benefit for the early detection/therapeutic targeting of prostate carcinoma (Figure 3 ). Our current understanding of prostate cancer chemoprevention is that treatment of the prostate with neoadjuvant androgen deprivation and a-estrogen antagonist seems to be effective in reducing both the prevalence and extent of HGPIN. Large clinical studies are currently in progress to explore potential therapeutic interventions aimed at targeting deregulated apoptosis in premalignant hyperlasia and prostate adenocarcinoma and to validate the use of selected apoptosis regulators as molecular tools for diagnosing prostate cancer. Further knowledge of the expression profile of specific apoptotic signaling effectors implicated in the regulation of prostate growth may provide crucial information on the therapeutic response and disease-free survival of patients with prostate cancer.
